Radiopharm Theranostics Limited (RADX)
| Market Cap | 53.30M +60.0% |
| Revenue (ttm) | 10.86M +4,823.5% |
| Net Income | -31.07M |
| EPS | -0.01 |
| Shares Out | 3.54B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,260 |
| Open | 4.570 |
| Previous Close | 4.640 |
| Day's Range | 4.460 - 4.720 |
| 52-Week Range | 3.620 - 16.250 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 17.83 (+289.3%) |
| Earnings Date | May 28, 2026 |
About RADX
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung the... [Read more]
Financial Performance
In fiscal year 2025, Radiopharm Theranostics's revenue was 12.51 million, an increase of 538.86% compared to the previous year's 1.96 million. Losses were -38.34 million, -20.04% less than in 2024.
Financial numbers in AUD Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RADX stock is "Strong Buy." The 12-month stock price target is $17.83, which is an increase of 289.30% from the latest price.
News
Radiopharm Theranostics Transcript: Deutsche Bank ADR Virtual Investor Conference
A differentiated radiopharmaceutical pipeline is advancing four clinical programs in parallel, with near-term catalysts expected from ongoing phase I and II trials. Imaging agent RAD 101 is nearing phase III and potential commercialization, while operational efficiency and strategic partnerships support growth.
Radiopharm Theranostics Slides: Deutsche Bank ADR Virtual Investor Conference
Radiopharm Theranostics has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Radiopharm Theranostics Transcript: Deutsche Bank ADR Virtual Investor Conference
A differentiated radiopharmaceutical pipeline is advancing four clinical programs in parallel, with near-term catalysts expected from ongoing phase I and II trials. Imaging agent RAD 101 is nearing phase III and potential commercialization, while operational efficiency and strategic partnerships support growth.
Radiopharm Theranostics Slides: Deutsche Bank ADR Virtual Investor Conference
Radiopharm Theranostics has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Radiopharm Theranostics Reports Business Update
Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (t...
Radiopharm Theranostics Earnings release: Q3 2026
Radiopharm Theranostics released its Q3 2026 earnings on April 22, 2026, summarizing the period's financial results.
Radiopharm Theranostics Earnings release: Q3 2026
Radiopharm Theranostics released its Q3 2026 earnings on April 22, 2026, summarizing the period's financial results.
Radiopharm announces new data from Phase 0/1 HEAT trial
Radiopharm (RADX) Theranostics announced that new data from the ongoing Phase 0/1 HEAT trial, evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, will be presented as ...
Radiopharm gets DSMC recommendation to advance 177Lu-RAD202 to next dose
Radiopharm (RADX) announced that it has received a recommendation from the Data Safety and Monitoring Committee, or DSMC, to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the nex...
Radiopharm Theranostics Signs Supply Deal With Siemens Healthineers For RAD101
(RTTNews) - Radiopharm Theranostics Ltd. (RADX) said Tuesday it has signed a supply agreement with Siemens Healthineers for RAD101, a novel imaging small molecule targeting fatty acid synthase (FASN) ...
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Radiopharm Theranostics (RADX), 2566.66% surge in interes...
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinica...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Radiopharm Theranostics (RADX), 2,318.18% surge in intere...
Radiopharm Theranostics Transcript: Study result
Interim phase II-B results for RAD101 in brain metastases show 90% of patients achieving the primary endpoint, with PET imaging providing clear diagnostic value over MRI, especially in equivocal cases. The study is nearing completion, with phase III preparations underway and strong commercial interest reported.
Radiopharm Theranostics Press release: Study result
Radiopharm Theranostics issued a press release on March 24, 2026, disclosing material business information to investors.
Radiopharm Theranostics Transcript: Study result
Interim phase II-B results for RAD101 in brain metastases show 90% of patients achieving the primary endpoint, with PET imaging providing clear diagnostic value over MRI, especially in equivocal cases. The study is nearing completion, with phase III preparations underway and strong commercial interest reported.
Radiopharm Theranostics Press release: Study result
Radiopharm Theranostics issued a press release on March 24, 2026, disclosing material business information to investors.
Radiopharm Theranostics Transcript: NWR Virtual Healthcare Conference
RAD101 phase II-B interim results showed strong efficacy in brain metastasis, with final data due by mid-year and phase III planning underway. Multiple first-in-class clinical programs are advancing, with key readouts for RAD204 and RAD202 expected by year-end.
Radiopharm Theranostics Transcript: NWR Virtual Healthcare Conference
RAD101 phase II-B interim results showed strong efficacy in brain metastasis, with final data due by mid-year and phase III planning underway. Multiple first-in-class clinical programs are advancing, with key readouts for RAD204 and RAD202 expected by year-end.
Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results
RAD 101 is Radiopharm's novel, small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from solid...
Radiopharm doses first patient in Phase 1/2a study of BetaBart
Radiopharm (RADX) Theranostics announced the dosing of the first patient in its First-In-Human, FIH, Phase 1/2a clinical trial of 177Lu-Betabart. The Phase 1/2a clinical trial is a dose escalation and
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases
Radiopharm Theranostics Earnings release: Q2 2026
Radiopharm Theranostics released its Q2 2026 earnings on January 27, 2026, summarizing the period's financial results.
Radiopharm Theranostics Earnings release: Q2 2026
Radiopharm Theranostics released its Q2 2026 earnings on January 27, 2026, summarizing the period's financial results.